People In The News

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics said this week that Brian Markison has become an observer to the company's board of directors and that he will become a director at the firm upon approval. Markison currently is chairman and CEO of King Pharmaceuticals, where he led the company through to its recently announced acquisition by Pfizer, and before that he was at Bristol-Myers Squibb, where he served as president of BMS Oncology/Virology and Oncology Therapeutics Network.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.